Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics (NQ: MRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirati Therapeutics

< Previous 1 2 3 4 5 6 7 8 Next >
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Investigation Announced for Long-Term Investors in Mirati Therapeutics, Inc. (NASDAQ:MRTX)
San Diego, CA -- (SBWIRE) -- 12/07/2021 -- Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
Expert Ratings For Mirati Therapeutics
Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst rating... 
Via Benzinga
Expert Ratings For Mirati Therapeutics
Over the past 3 months, 5 analysts have published their opinion on Mirati Therapeutics (NASDAQ: 
Via Benzinga
New CEO At Mirati Therapeutics
Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc (NASDAQ: MRTX) has appointed David Meek as Chief Executive Officer,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Mirati Posts More Responses For Adagrasib-Keytruda Combo In Lung Cancer Setting
In its Q3 earnings release, Mirati Therapeutics Inc (NASDAQ: MRTX) posted preliminary results from the Phase 1b cohort of the KRYSTAL-1 study evaluating adagrasib... 
Via Benzinga
NASDAQ:MRTX Investor Notice: Investigation over Possible Securities Laws Violations by Mirati Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 11/08/2021 -- Mirati Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Mid-Afternoon Market Update: loanDepot Surges After Q3 Results; Mirati Therapeutics Shares Slide
Toward the end of trading Monday, the Dow traded up 0.12% to 35,863.70 while the NASDAQ rose 0.18% to 15,525.52. The S&P, however, fell 0.10% to 4,600.81. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's regular session. As of 12:30 EST, this security is trading at a volume... 
Via Benzinga
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock is seeing increased interest by traders on... 
Via Benzinga
Mid-Day Market Update: Dow Rises 50 Points; ANI Pharmaceuticals Shares Jump
Midway through trading Monday, the Dow traded up 0.14% to 35,871.27 while the NASDAQ rose 0.23% to 15,534.49. The S&P also fell, dropping 0.03% to 4,603.98. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
40 Stocks Moving In Monday's Mid-Day Session
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares jumped 250% to $8.91 on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the... 
Via Benzinga
Mirati Therapeutics COO, CMO Exit, Completing Management Overhaul
Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) are retreating sharply Monday following two executive departures. What Happened: Mirati, a clinical-stage targeted oncology... 
Via Benzinga
Here's My Top Value Stock To Buy Right Now
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications. 
Via Talk Markets
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal... 
Via Benzinga
What 6 Analyst Ratings Have To Say About Mirati Therapeutics
Over the past 3 months, 6 analysts have published their opinion on Mirati Therapeutics (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
RBC Capital boosted MSCI Inc. (NYSE:MSCI) price tar... 
Via Benzinga
Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer
Mirati Therapeutics easily beat Amgen's test results in colon cancer. 
Via Investor's Business Daily
Why Mirati Therapeutics Stock Is Trading Higher Today
Mirati Therapeutics Inc (NASDAQ: MRTX) is trading higher Monday after the company announced clinical data with investigational adagrasib as monotherapy and in combination... 
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company... 
Via Benzinga
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.